Immunopharmacology: Foundations and Cytokine Pharmacology

Correct Answer

C — Etanercept

Rationale

Etanercept is classified as a fusion protein, not a monoclonal antibody. It consists of the extracellular domain of the tumor necrosis factor receptor 2 linked to an immunoglobulin G1 Fc region, and it binds both tumor necrosis factor-alpha and lymphotoxin-alpha. Adalimumab is a fully human monoclonal antibody targeting tumor necrosis factor-alpha. Infliximab is a chimeric monoclonal antibody targeting tumor necrosis factor-alpha. Golimumab is a fully human monoclonal antibody targeting tumor necrosis factor-alpha. Recognizing etanercept as a receptor fusion protein rather than a monoclonal antibody is clinically important because this structural class difference underlies its distinct pharmacological profile compared to the monoclonal tumor necrosis factor inhibitors.

Correct Answer

D — Ustekinumab

Rationale

Ustekinumab is classified as an anti-p40 monoclonal antibody. Interleukin-12 and interleukin-23 share the p40 subunit, so ustekinumab blocks both cytokines with a single agent. Secukinumab targets interleukin-17A. Risankizumab targets the p19 subunit of interleukin-23 specifically, leaving interleukin-12 unaffected. Tocilizumab targets the interleukin-6 receptor alpha chain.

Correct Answer

A — Eculizumab

Rationale

Eculizumab is classified as an anti-C5 monoclonal antibody that blocks cleavage of complement component C5. Anakinra is an interleukin-1 receptor antagonist. Tocilizumab targets the interleukin-6 receptor alpha chain. Belimumab targets B-cell activating factor, a survival signal for B lymphocytes.

Correct Answer

C — Anakinra

Rationale

Anakinra is classified as recombinant interleukin-1 receptor antagonist. It blocks both interleukin-1 alpha and interleukin-1 beta by occupying the shared interleukin-1 receptor. Canakinumab is a monoclonal antibody selective for interleukin-1 beta. Rilonacept is a soluble decoy receptor fusion protein that traps interleukin-1 alpha and interleukin-1 beta. Tocilizumab targets the interleukin-6 receptor and is not an interleukin-1 pathway agent.

Correct Answer

A — Baricitinib

Rationale

Baricitinib is classified as a Janus kinase 1 and Janus kinase 2 inhibitor. Tofacitinib preferentially inhibits Janus kinase 1 and Janus kinase 3. Upadacitinib is a selective Janus kinase 1 inhibitor with minimal activity at other isoforms. Filgotinib is also a preferential Janus kinase 1 inhibitor and does not share the Janus kinase 1 and Janus kinase 2 selectivity profile that defines baricitinib.

Correct Answer

C — Dupilumab

Rationale

Dupilumab is classified as a monoclonal antibody targeting the interleukin-4 receptor alpha chain, which is shared by the receptors for both interleukin-4 and interleukin-13. Mepolizumab targets interleukin-5. Benralizumab targets the interleukin-5 receptor alpha subunit. Secukinumab targets interleukin-17A.

Correct Answer

B — Interleukin-6 receptor blockade prevents hepatic synthesis of C-reactive protein

Rationale

Interleukin-6 is the primary driver of hepatic acute-phase protein synthesis, including C-reactive protein and fibrinogen. Tocilizumab and sarilumab block the interleukin-6 receptor alpha chain, preventing interleukin-6 from signaling to hepatocytes. As a result, C-reactive protein levels remain low even when active infection is present, making this biomarker unreliable in patients on interleukin-6 receptor inhibitors. Procalcitonin and clinical assessment must be used instead to evaluate for infection in these patients.

Correct Answer

C — Etanercept is ineffective in Crohn's disease and other granulomatous conditions, unlike the monoclonal tumor necrosis factor inhibitors

Rationale

Although etanercept effectively inhibits tumor necrosis factor-alpha and is approved for ankylosing spondylitis, it is clinically ineffective in granulomatous diseases, including Crohn's disease and sarcoidosis. The monoclonal tumor necrosis factor inhibitors — infliximab, adalimumab, golimumab, and certolizumab — are approved for both inflammatory bowel disease and spondyloarthropathies and represent the appropriate class when both conditions require treatment. Etanercept is not contraindicated in ankylosing spondylitis; it is an approved and effective option for that indication. Etanercept does inhibit tumor necrosis factor-alpha; the claim that it does not is incorrect. Etanercept is administered by subcutaneous injection, not intravenous infusion.

Correct Answer

A — Interleukin-17A contributes to mucosal barrier integrity in the gut, and its blockade can worsen intestinal inflammation

Rationale

Interleukin-17A drives neutrophilic inflammation at epithelial surfaces and plays a role in maintaining mucosal barrier defense in the gastrointestinal tract. When secukinumab or ixekizumab blocks interleukin-17A, this mucosal protective role is disrupted, which can precipitate new-onset or worsen pre-existing inflammatory bowel disease. This is a class-specific risk of interleukin-17A inhibitors and is listed as a contraindication in patients with active inflammatory bowel disease. Ustekinumab, which blocks the interleukin-23/interleukin-17A axis upstream, is an alternative that is actually approved for Crohn's disease and ulcerative colitis.

Correct Answer

B — Anemia and neutropenia

Rationale

Anemia and neutropenia are recognized class adverse effects of Janus kinase inhibitors and are included in the prescribing information for baricitinib, tofacitinib, and upadacitinib as findings that require monitoring with periodic complete blood counts. Janus kinase signaling is required downstream of multiple hematopoietic growth factor receptors, and its inhibition at clinical doses suppresses the cytokine-driven signals that govern red cell and granulocyte production. Eosinophilia, basophilia, polycythemia, thrombocytosis, lymphocytosis, and monocytosis are not class effects of Janus kinase inhibitors. Thrombocytopenia may also occur but is less consistently reported than anemia and neutropenia across the approved agents.

Correct Answer

B — Mepolizumab blocks interleukin-5, which governs eosinophil production, maturation, and survival

Rationale

Mepolizumab is a monoclonal antibody that binds interleukin-5 and prevents it from interacting with the interleukin-5 receptor on eosinophils and their bone marrow precursors. Interleukin-5 is the principal cytokine driving eosinophil production in the bone marrow, eosinophil maturation, and eosinophil survival in peripheral blood and tissues. By blocking interleukin-5, mepolizumab substantially reduces circulating and airway eosinophil counts. Reslizumab also targets interleukin-5, while benralizumab targets the interleukin-5 receptor alpha chain directly.

Correct Answer

D — Eculizumab blocks C5 cleavage, preventing formation of the membrane attack complex that lyses encapsulated bacteria

Rationale

Eculizumab binds complement component C5 and prevents its cleavage into C5a and C5b. C5b is the nucleating component of the membrane attack complex, the terminal effector that punches lethal pores in bacterial membranes. Encapsulated organisms such as Neisseria meningitidis and Neisseria gonorrhoeae are uniquely dependent on membrane attack complex-mediated killing for clearance; patients lacking terminal complement function are highly susceptible to these organisms. Eculizumab preserves upstream C3b-mediated opsonization, so phagocytic killing is intact, but direct bactericidal killing via the membrane attack complex is lost. Meningococcal vaccination against serogroups A, C, W, Y, and B is required before starting eculizumab, with antibiotic prophylaxis recommended throughout therapy.

Correct Answer

A — Canakinumab is a monoclonal antibody with a half-life of approximately 26 days, while anakinra is a recombinant protein with a short half-life

Rationale

The dosing schedule difference reflects a pharmacokinetic difference in half-life. Canakinumab is a full monoclonal IgG1 antibody selective for interleukin-1 beta; its half-life of approximately 26 days allows monthly or quarterly subcutaneous dosing with sustained interleukin-1 beta blockade. Anakinra is a recombinant form of the endogenous interleukin-1 receptor antagonist; its short half-life requires daily subcutaneous injection to maintain therapeutic concentrations. This short half-life also makes anakinra useful in situations where rapid offset of effect is desirable, such as acute flares of gout, pericarditis, or cytokine storm syndromes.

Correct Answer

D — Monosodium urate crystals trigger innate immune cells to generate interleukin-1 beta, which is the principal cytokine driving the acute articular inflammation of gout

Rationale

When monosodium urate crystals are deposited in the joint and phagocytosed by macrophages and other innate immune cells in the synovium, intracellular danger-sensing pathways are activated and interleukin-1 beta is generated and secreted. Interleukin-1 beta is the principal cytokine responsible for the intense neutrophilic inflammation, pain, and swelling of an acute gout flare, which is why blocking the interleukin-1 pathway with canakinumab, anakinra, or rilonacept produces rapid suppression of symptoms in flares refractory to conventional agents. Gout flares are driven by innate immune activation, not by T-lymphocyte-mediated adaptive immunity. Interleukin-1 beta inhibitors do not lower serum uric acid and do not prevent crystal deposition; they act on the downstream inflammatory response. Interleukin-1 beta in gout is produced primarily by macrophages, not by synovial fibroblasts.

Correct Answer

A — Certolizumab pegol, because it is not actively transported across the placenta and results in negligible fetal drug levels

Rationale

Active placental transport of immunoglobulin G antibodies is mediated by neonatal Fc receptors on placental cells, and transfer increases substantially in the third trimester. Certolizumab pegol lacks an Fc region entirely and is therefore not a substrate for this transport mechanism; studies have confirmed negligible drug levels in cord blood and neonatal samples. It is the preferred tumor necrosis factor inhibitor when minimizing fetal exposure is a clinical priority. Infliximab, adalimumab, and golimumab are full immunoglobulin G1 monoclonal antibodies that are actively transported across the placenta; fetal drug concentrations can equal or exceed maternal levels by the third trimester. The degree of placental transfer for full monoclonal antibodies is not meaningfully affected by whether the antibody is chimeric or fully human. Etanercept retains an immunoglobulin G1 Fc region and undergoes some degree of placental transfer, though cord blood levels are generally lower than with the full monoclonal antibodies.

Correct Answer

C — Interleukin-17A inhibitors

Rationale

Interleukin-17A inhibitors (secukinumab and ixekizumab) carry a class-specific risk of new-onset or worsening inflammatory bowel disease and are contraindicated in patients with active Crohn's disease or ulcerative colitis. Interleukin-17A contributes to mucosal barrier defense in the gut, and its blockade disrupts this protective function. Tumor necrosis factor inhibitors such as adalimumab and infliximab are approved for both psoriasis and Crohn's disease and are appropriate options. Ustekinumab (anti-p40, blocking interleukin-12 and interleukin-23) is approved for both conditions. Interleukin-23 p19 inhibitors are approved for psoriasis and do not carry the inflammatory bowel disease contraindication of interleukin-17A inhibitors.

Correct Answer

A — Janus kinase inhibition impairs T-cell signaling and increases herpes zoster reactivation risk, so vaccination should be completed while immune function is intact

Rationale

Herpes zoster reactivation is the most common infectious complication of Janus kinase inhibitors. Because Janus kinase signaling is essential for cytokine-driven T-cell activation and proliferation, Janus kinase inhibitors impair the T-cell-mediated immunity that keeps latent varicella-zoster virus in check. The recombinant zoster vaccine (Shingrix) is a non-live adjuvanted subunit vaccine, so it is safe to administer even in immunocompromised patients; however, it is recommended before initiating Janus kinase inhibitor therapy because immune responses to vaccination are stronger when T-cell function is not yet suppressed. Shingrix is a non-live recombinant subunit vaccine and is not contraindicated during Janus kinase inhibitor therapy, but pre-treatment vaccination produces a stronger immune response when T-cell function is fully intact.

Correct Answer

C — Treat latent tuberculosis before initiating tofacitinib, because Janus kinase inhibitors carry a black box warning for tuberculosis reactivation

Rationale

Janus kinase inhibitors carry a class-wide black box warning for serious infections, including reactivation of latent tuberculosis. Mandatory pre-treatment screening with a tuberculin skin test or interferon-gamma release assay is required; a positive result in the absence of active disease on imaging indicates latent infection that must be treated with an appropriate regimen before tofacitinib is started. A normal chest radiograph does not eliminate the need to treat latent tuberculosis — it confirms only the absence of active pulmonary disease. Biologic tumor necrosis factor inhibitors carry an equivalent or greater risk of tuberculosis reactivation and require identical pre-treatment screening; switching to a tumor necrosis factor inhibitor does not resolve the latent tuberculosis problem. Repeating the tuberculin skin test is unnecessary when the initial result is unambiguously positive.